Abstract
Renal cell carcinoma (RCC) has been classically characterized by its resistance to traditional chemotherapy, radiotherapy, and hormonal therapy treatments. Cytokine therapy has showed therapeutic benefit in a small percentage of RCC patients. The discovery of key molecular pathways involved in the tumorigenesis of RCC has favored the development of new and more effective therapies. The most successful molecular target identified so far is the von Hippel–Lindau (VHL)/hypoxia-inducible factor (HIF)/vascular endothelial growth factor (VEGF) pathway, which is known to be altered in most patients with sporadic clear-cell RCC. In the past 6 years, the use of targeted therapies has significantly increased the treatment options for patients with mRCC and improved their perspectives. Sorafenib, the first new generation targeted treatment, received Food and Drug Administration (FDA) approval in 2005 for patients with cytokine-refractory disease. Following sorafenib approval, three other VEGF-targeted agents—sunitinib, bevacizumab, and pazopanib—have been approved for the treatment of metastatic RCC. Currently, these targeted therapies have replaced the use of immunotherapy in the vast majority of mRCC patients.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Coppin C, Porzsolt F, Awa A et al (2005) Immunotherapy for advanced renal cell cancer. Cochrane Database Syst Rev (1):CD001425
Knudson AG Jr (1986) Genetics of human cancer. Annu Rev Genet 20:231–251
Shuin T, Kondo K, Torigoe S et al (1994) Frequent somatic mutations and loss of heterozygosity of the von Hippel-Lindau tumor suppressor gene in primary human renal cell carcinomas. Cancer Res 54(11):2852–2855
Herman JG, Latif F, Weng Y et al (1994) Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma. Proc Natl Acad Sci USA 91(21):9700–9704
Nickerson ML, Jaeger E, Shi Y, Durocher JA et al (2008) Improved identification of von Hippel-Lindau gene alterations in clear cell renal tumors. Clin Cancer Res 14(15):4726–4734
Maher ER (2004) Von Hippel-Lindau disease. Curr Mol Med 4(8):833–842
Brauch H, Weirich G, Brieger J et al (2000) VHL alterations in human clear cell renal cell carcinoma: association with advanced tumor stage and a novel hot spot mutation. Cancer Res 60(7):1942–1948
Schraml P, Struckmann K, Hatz F et al (2002) VHL mutations and their correlation with tumour cell proliferation, microvessel density, and patient prognosis in clear cell renal cell carcinoma. J Pathol 196(2):186–193
Kiselyov A, Balakin KV, Tkachenko SE (2007) VEGF/VEGFR signalling as a target for inhibiting angiogenesis. Expert Opin Investig Drugs 16(1):83–107
Dvorak HF, Detmar M, Claffey KP et al (1995) Vascular permeability factor/vascular endothelial growth factor: an important mediator of angiogenesis in malignancy and inflammation. Int Arch Allergy Immunol 107(1–3):233–235
Takahashi A, Sasaki H, Kim SJ et al (1994) Markedly increased amounts of messenger RNAs for vascular endothelial growth factor and placenta growth factor in renal cell carcinoma associated with angiogenesis. Cancer Res 54(15):4233–4237
Nicol D, Hii SI, Walsh M, Teh B et al (1997) Vascular endothelial growth factor expression is increased in renal cell carcinoma. J Urol 157(4):1482–1486
Ferrara N, Hillan KJ, Gerber HP et al (2004) Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 3(5):391–400
Yang JC, Haworth L, Sherry RM et al (2003) A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 349(5):427–434
Escudier B, Pluzanska A, Koralewski P et al (2007) Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 370:2103–2111
Escudier B, Bellmunt J, Négrier S et al (2010) Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival. J Clin Oncol 28(13):2144–2150
Motzer RJ, Bacik J, Murphy BA et al (2002) Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 20:289–296
Rini BI, Halabi S, Rosenberg JE et al (2008) Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J Clin Oncol 26:5422–5428
Rini BI, Halabi S, Rosenberg JE et al (2010) Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206. J Clin Oncol 28(13):2137–2143
Melichar B, Koralewski P, Ravaud A et al (2008) First-line bevacizumab combined with reduced dose interferon-alpha2a is active in patients with metastatic renal cell carcinoma. Ann Oncol 19(8):1470–1476
Melichar B, Bracarda S, Matveev V et al (2011) BEVLiN: prospective study of the safety and efficacy of first-line bevacizumab (BEV) plus low-dose interferon-α2a (IFN) in patients (pts) with metastatic renal cell carcinoma (mRCC). J Clin Oncol 29(suppl): abstract 4546
Hainsworth JD, Sosman JA, Spigel DR et al (2005) Treatment of metastatic renal cell carcinoma with a combination of bevacizumab and erlotinib. J Clin Oncol 23(31):7889–7896
Bukowski RM, Kabbinavar FF, Figlin RA et al (2007) Randomized phase II study of erlotinib combined with bevacizumab compared with bevacizumab alone in metastatic renal cell cancer. J Clin Oncol 25(29):4536–4541
Hainsworth JD, Spigel DR, Sosman JA et al (2007) Treatment of advanced renal cell carcinoma with the combination bevacizumab/erlotinib/imatinib: a phase I/II trial. Clin Genitourin Cancer 5(7):427–432
Hainsworth JD, Spigel DR, Burris HA 3rd et al (2010) Phase II trial of bevacizumab and everolimus in patients with advanced renal cell carcinoma. J Clin Oncol 28(13):2131–2136
Merchan JR, Pitot HC, Qin R et al (2009) Phase I/II trial of CCI 779 and bevacizumab in advanced renal cell carcinoma (RCC): safety and activity in RTKI refractory RCC patients. J Clin Oncol 27(15s):244s, abstract 5039
Escudier B, Negrier S, Gravis G et al (2010) Can the combination of temsirolimus and bevacizumab improve the treatment of metastatic renal cell carcinoma (mRCC)? Results of the randomized TORAVA phase II trial. J Clin Oncol 28(suppl):15s, abstract 4516
Feldman DR, Baum MS, Ginsberg MS et al (2009) Phase I trial of bevacizumab plus escalated doses of sunitinib in patients with metastatic renal cell carcinoma. J Clin Oncol 27(9):1432–1439
Rini BI, Garcia JA, Cooney MM et al (2009) A phase I study of sunitinib plus bevacizumab in advanced solid tumors. Clin Cancer Res 15(19):6277–6283
Azad NS, Posadas EM, Kwitkowski VE et al (2008) Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity. J Clin Oncol 26(22):3709–3714
Sosman JA, Flaherty KT, Atkins MB (2008) Updated results of phase I trial of sorafenib (S) and bevacizumab (B) in patients with metastatic renal cell cancer (mRCC). J Clin Oncol 26(suppl):252s, abstract 5011
Tamaskar I, Rini B, Mekhail T et al (2008) A phase II trial of low-dose interleukin-2 (IL-2) and bevacizumab for patients (pts) with metastatic renal cell carcinoma (mRCC). Genitourinary Cancers Symposium, San Francisco, California, February 14–16. Abstract 363
Dandamudi UB, Ghebremichael MS, Sosman JA (2010) A phase II study of bevacizumab (B) and high-dose aldesleukin (IL-2) in patients (p) with metastatic renal cell carcinoma (mRCC): a Cytokine Working Group Study (CWGS). J Clin Oncol 28(suppl):15s, abstract 4530
Garcia JA, Mekhail T, Elson P et al (2011) Clinical and immunomodulatory effects of bevacizumab and low-dose interleukin-2 in patients with metastatic renal cell carcinoma: results from a phase II trial. BJU Int 107(4):562–570
Mendel DB, Laird AD, Xin X et al (2003) In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 9:327–337
Rosen L, Mulay M, Long J et al (2003) Phase I trial of SU011248, a novel tyrosine kinase inhibitor in advanced solid tumors. Proc Am Soc Clin Oncol 22: abstract 765
Faivre S, Delbaldo C, Vera K et al (2006) Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol 24(1):25–35
Motzer RJ, Michaelson MD, Redman BG et al (2006) Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 24(1):16–24
Motzer RJ, Rini BI, Bukowski RM et al (2006) Sunitinib in patients with metastatic renal cell carcinoma. JAMA 295(21):2516–2524
Motzer RJ, Hutson TE, Tomczak P et al (2007) Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356(2):115–124
Motzer RJ, Hutson TE, Tomczak P et al (2009) Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 27(22):3584–3590
Gore ME, Szczylik C, Porta C et al (2009) Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial. Lancet Oncol 10(8):757–763
Motzer RJ, Hutson TE, Olsen MR et al (2011) Randomized phase II multicenter study of the efficacy and safety of sunitinib on the 4/2 versus continuous dosing schedule as first-line therapy of metastatic renal cell carcinoma: renal EFFECT trial. J Clin Oncol 29(suppl 7): abstract LBA308
Rini BI, Cohen DP, Lu DR et al (2011) Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst 103(9):763–773
Wilhelm SM, Carter C, Tang L et al (2004) BAY43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 64:7099–7109
Strumberg D, Richly H, Hilger RA et al (2005) Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43–9006 in patients with advanced refractory solid tumors. J Clin Oncol 23(5):965–972
Clark JW, Eder JP, Ryan D et al (2005) Safety and pharmacokinetics of the dual action Raf kinase and vascular endothelial growth factor receptor inhibitor, BAY 43–9006, in patients with advanced, refractory solid tumors. Clin Cancer Res 11(15):5472–5480
Moore M, Hirte HW, Siu L et al (2005) Phase I study to determine the safety and pharmacokinetics of the novel Raf kinase and VEGFR inhibitor BAY 43–9006, administered for 28 days on/7 days off in patients with advanced, refractory solid tumors. Ann Oncol 16(10):1688–1694
Awada A, Hendlisz A, Gil T et al (2005) Phase I safety and pharmacokinetics of BAY 43–9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumors. Br J Cancer 92(10):1855–1861
Ratain MJ, Eisen T, Stadler WM et al (2006) Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 24(16):2505–2512
Escudier B, Eisen T, Stadler WM et al (2007) Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356:125–134
Escudier B, Eisen T, Stadler WM et al (2009) Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol 27:3312–3318
Sonpavde G, Hutson TE (2007) Pazopanib: a novel multitargeted tyrosine kinase inhibitor. Curr Oncol Rep 9:115–119
Hurwitz HI, Dowlati A, Saini S et al (2009) Phase I trial of pazopanib in patients with advanced cancer. Clin Cancer Res 15(12):4220–4227
Hutson TE, Davis ID, Machiels JP et al (2010) Efficacy and safety of pazopanib in patients with metastatic renal cell carcinoma. J Clin Oncol 28(3):475–480
Sternberg CN, Davis ID, Mardiak J et al (2010) Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol 28(6):1061–1068
Stenberg C, Hawkins R, Szczylk C et al. (2010) Randomized, double blind phase III study of pazopanib in patients with advanced/metastatic renal cell carcinoma (MRCC): final overall survival (OS) results. Paper presented at the 2010 European Society for Medical Oncology (ESMO) annual meeting, Milan, 8–10.
Pazopanib versus sunitinib in the treatment of locally advanced and/or metastatic renal cell carcinoma (NCT00720941) June 2011. http://www.clinicaltrials.gov
Patient preference study of pazopanib versus sunitinib in advanced or metastatic kidney cancer (NCT01064310). June 2011. http://www.clinicaltrials.gov
Escudier B, Cella D, Gschwend J et al (2010) A randomized double-blind cross-over patient preference study of pazopanib versus sunitinib in treatment-naive locally advanced or metastatic renal cell carcinoma (mRCC). J Clin Oncol 28(suppl):15s, abstract TPS237
Rugo HS, Herbst RS, Liu G et al (2005) Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results. J Clin Oncol 23:5474–5783
Rixe O, Bukowski RM, Michaelson MD et al (2007) Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study. Lancet Oncol 8:975–984
Rini B, Wilding GT, Hudes G et al (2009) Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma. J Clin Oncol 27:4462–4468
Rixe O, Dutcher J, Motzer R et al (2009) Diastolic blood pressure (dBP) and pharmacokinetics (PK) as predictors of axitinib efficacy in metastatic renal cell cancer (mRCC). J Clin Oncol 27(suppl):15s, abstract 5045
Rini BI, Escudier B, Tomczak P et al (2011) Axitinib versus sorafenib as second-line therapy for metastatic renal cell carcinoma (mRCC): results of phase III AXIS trial. J Clin Oncol 29(suppl):15s, abstract 4503
Axitinib (AG-013736) with or without dose titration (Increase) in patients with kidney cancer (NCT00835978). June 2011. http://www.clinicaltrials.gov
Axitinib (AG-013736) for the treatment of metastatic renal cell cancer (NCT00920816). June 2011. http://www.clinicaltrials.gov
Nakamura K, Taguchi E, Miura T et al (2006) KRN951, a highly potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, has antitumor activities and affects functional vascular properties. Cancer Res 66(18):9134–9142
Eskens F, de Jorge M, Esteves B et al (2008) Updated results from a phase I study of AV-951 (KRN951), a potent and selective VEGFR-1, -2 and −3 tyrosine kinase inhibitor, in patients with advanced solid tumors. AACR Meeting Abstracts, Apr 2008: LB-201
Bhargava P, Esteves B, Al-Adhami M et al. Effect of hypertension, nephrectomy, and prior treatment on the efficacy of tivozanib (AV-951) in a phase II randomized discontinuation trial (RDT) in patients with renal cell carcinoma (RCC). Genitourinary Cancers Symposium, San Francisco, California, March 5–7. Abstract 342
Bhargava P, Esteves B, Al-Adhami M et al (2010) Activity of tivozanib (AV-951) in patients with renal cell carcinoma (RCC): subgroup analysis from a phase II randomized discontinuation trial (RDT). J Clin Oncol 28(suppl):15s, abstract 4599
Motzer R, Bhargava P, Esteves B et al (2011) A phase III, randomized, controlled study to compare tivozanib with sorafenib in patients (pts) with advanced renal cell carcinoma (RCC). J Clin Oncol 29(suppl 7): abstract 310
Lindsay CR, MacPherson IR, Cassidy J (2009) Current status of cediranib: the rapid development of a novel anti-angiogenic therapy. Future Oncol 5(4):421–432
Drevs J, Siegert P, Medinger M et al (2007) Phase I clinical study of AZD2171, an oral vascular endothelial growth factor signaling inhibitor, in patients with advanced solid tumors. J Clin Oncol 25(21):3045–3054
Sridhar S, Mackenzie M, Hotte S et al (2008) Activity of cediranib (AZD2171) in patients (pts) with previously untreated metastatic renal cell cancer (RCC). A phase II trial of the PMH Consortium. J Clin Oncol 26(suppl): abstract 5047
Lee SH, de Lopes MD, Vora J et al (2005) In vivo target modulation and biological activity of CHIR-258, a multitargeted growth factor receptor kinase inhibitor, in colon cancer models. Clin Cancer Res 11:3633–3641
Korc M, Friesel RE (2009) The role of fibroblast growth factors in tumor growth. Curr Cancer Drug Targets 9(5):639–651
Angevin E, Lin C, Pande A et al (2010) A phase I/II study of dovitinib (TKI258), a FGFR and VEGFR inhibitor, in patients (pts) with advanced or metastatic renal cell cancer: phase I results. J Clin Oncol 28(suppl):15s, abstract 3057
Motzer RJ, Hudes G, Wilding G et al (2009) Phase I trial of sunitinib malate plus interferon-alpha for patients with metastatic renal cell carcinoma. Clin Genitourin Cancer 7(1):28–33
Patel PH, Senico PL, Curiel RE, Motzer RJ (2009) Phase I study combining treatment with temsirolimus and sunitinib malate in patients with advanced renal cell carcinoma. Clin Genitourin Cancer 7(1):24–27
Kroog G, Feldman D, Kondagunta G et al (2009) Phase I trial of RAD001 (everolimus) plus sunitinib in patients with metastatic renal cell carcinoma. J Clin Oncol 27(suppl):15s, abstract 5037
Molina A, Feldman D, Ginsberg M et al (2011) Phase I trial sunitinib plus everolimus in patients with metastatic renal cell carcinoma (mRCC). J Clin Oncol 29(suppl 7): abstract 311
Rini BI, Stein M, Shannon P et al (2011) Phase 1 dose-escalation trial of tremelimumab plus sunitinib in patients with metastatic renal cell carcinoma. Cancer 117(4):758–767
Escudier B, Lassau N, Angevin E et al (2007) Phase I trial of sorafenib in combination with IFN alpha-2a in patients with unresectable and/or metastatic renal cell carcinoma or malignant melanoma. Clin Cancer Res 13(6):1801–1809
Gollob JA, Rathmell WK, Richmond TM et al (2007) Phase II trial of sorafenib plus interferon alfa-2b as first- or second-line therapy in patients with metastatic renal cell cancer. J Clin Oncol 25(22):3288–3295
Procopio G, Verzoni E, Bracarda S et al (2009) A randomized, open label, prospective study comparing the association between sorafenib (So) and interleukin-2 (IL-2) versus So alone in advanced untreated renal cell cancer (RCC): Rosorc Trial. J Clin Oncol 27(suppl):15s, abstract 5099
Lam E, Lesinski G, Mortazavi A et al (2011) Phase I study of high-dose interleukin (HD-IL2) and sorafenib in patients with metastatic clear cell renal cell carcinoma (RCC) and melanoma. J Clin Oncol 29(suppl 7): abstract 337
Patnaik A, Ricart A, Cooper J et al (2007) A phase I, pharmacokinetic and pharmacodynamic study of sorafenib (S), a multi-targeted kinase inhibitor in combination with temsirolimus (T), an mTOR inhibitor in patients with advanced solid malignancies. J Clin Oncol 25(suppl): abstract 3512
Cen P, Daleiden A, Doshi G et al (2009) A phase I study of everolimus plus sorafenib in patients with metastatic renal cell carcinoma (mRCC). J Clin Oncol 27(suppl): abstract e16056
Harzstark A, Rosenberg J, Weinberg V et al (2009) A phase I study of sorafenib and RAD001 for metastatic clear cell renal cell carcinoma. J Clin Oncol 27(suppl):15s, abstract 5104
Rini B, Szczylik C, Tannir N et al (2011) AMG 386 in combination with sorafenib in patients (pts) with metastatic renal cell cancer (mRCC): a randomized, double-blind, placebo-controlled, phase II study. J Clin Oncol 29(suppl 7): abstract 309
Kabbinavar F, Srinivas S, Hauke R et al (2011) A phase I trial of combined tivozanib (AV-951) and temsirolimus therapy in patients (pts) with renal cell carcinoma (RCC). J Clin Oncol 29(suppl 7): abstract 330
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2012 Springer Science+Business Media, LLC
About this chapter
Cite this chapter
Suarez, C., Rini, B.I. (2012). Targeting the VEGF Pathway in Renal Cell Carcinoma. In: Figlin, R., Rathmell, W., Rini, B. (eds) Renal Cell Carcinoma. Springer, Boston, MA. https://doi.org/10.1007/978-1-4614-2400-0_6
Download citation
DOI: https://doi.org/10.1007/978-1-4614-2400-0_6
Published:
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4614-2399-7
Online ISBN: 978-1-4614-2400-0
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)